Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

January 20, 2018

Primary Completion Date

November 30, 2025

Study Completion Date

February 1, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Cetuximab + FOLFIRI

Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.

Trial Locations (1)

Unknown

RECRUITING

Taleqani Hospital, Tehran

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cinnagen

INDUSTRY